IMR Press / EJGO / Volume 19 / Issue 2 / pii/1998133

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on as a courtesy and upon agreement with S.O.G.

Case Report

Expression of p53 protein in borderline epithelial ovarian tumors: a clinicopathologic study of 39 cases

Show Less
1 Service de Gynécologie, h?pital Bichat-Claude Bernard, France
2 Service d’Anatomie Pathologique, h?pital Bichat-Claude Bernard, France
3 Delegation à l’ évaluation médicale, Assistance Publique des h?pitaux de Paris, France
4 Laboratoire de Biologie Cellulaire, Faculté Xavier Bichat, France
Eur. J. Gynaecol. Oncol. 1998, 19(2), 144–149;
Published: 10 April 1998

Objective: To evaluate the expression of p53 protein in borderline ovarian tumors and its correlations with the clinicopathological parameters. Study design: p53 protein was detected by immunoperoxidase in 79 ovarian tumors (39 borderline, 20 malignant, 20 benign). p53expression was compared to histological type, FIGO stage, age, presence of ascites: recurrence and patient smvıval. Results: The median value of quantitative p53 immunopositivity was: 0.80 ± 0.42 in ovaıan cancers, 0 ± 0.24 m borderlme tumors and 0 ± 0.16 in benign tumors (p = 0.001). In borderline tumors, no correlation existed between p53 expression and the histological or clinical parameters. In malignant tumors, no correlation existed between the expression of p53 and patient survival. Conclusion: We found no correlation between p53 immunopositivity and clinicopathological parameters in carcinomas and bor­derline tumors of the ovary. p53 immunopositivity may help in distinguishing borderline tumors from ovarian cancers.

p53 protein
Borderline ovarian tumor
Ovarian cancer
Benign ovarian tumor
Back to top